Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report 1 January to 30 June 2021

Financial Summary for the groupKSEK Q2 Q2 Q1-Q2 Q1-Q2 2021 2020 2021 2020Profit/loss before tax -11 458 -14 197 -20 069 -24 394Total assets 69 240 58 357 69 240 58 357Earnings per share before -0,19 -0,29 -0,34 -0,50and after dilution (SEK)Cash and cash equivalents 54 054 41 611 54 054 41 611as per period endEquity ratio as per 92,6% 89,3% 92,6% 89,3%period end Significant events during the second quarter of 2021 · World leading

BoMill publishes half-year report for second quarter and first six months 2021

BoMill AB (”BoMill” or the “Company”) hereby publishes the half-year report for the second quarter and the first six months of 2021. The half-year report is available as an attached file to this release and on BoMill’s website. Below is a summary of the report.CEO Andreas Jeppsson comments: “We are very motivated in the journey that lies ahead of us. With the knowledge that the entire market is in a need of modernized technology, the timing is right. I am excited about or ongoing development and our business strategy, delivering value to producers, grain handlers, the processing industry

Sedana Medical's Sedaconda study published in the Lancet

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the results of the company's pivotal study Sedaconda (SED001) have been published in the highly ranked scientific journal, the Lancet Respiratory Medicine."We are very pleased that the study is published in Lancet Respiratory Medicine. The results of the study, which is the largest in inhaled sedation, point to the efficacy and safety of isoflurane via AnaConDa as well as the benefits of the therapy, namely reduced need of opioids, increased spontaneous breathing and faster awakening. Overall, there are now strong reasons

Scandion Oncology receives German trial approval for PANTAX Ib study

Scandion Oncology A/S today announced that the company has obtained approval from the German regulatory authorities to initiate clinical trials in Germany with SCO-101 in the PANTAX Ib study.The German medicines agency (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) and the German ethics committee have given approval, allowing Scandion Oncology to expand the PANTAX Ib study to Germany. “We are very pleased to receive this German approval as BfArM is highly regarded and known for having tough critera. The approval is important for the PANTAX Ib study, but it also opens the

SynAct Pharma: Interim Report January-June 2021 August 27, 2021

“Positive data of AP1189 in Covid-19 patients bodes well for the future. The hard work at the start of the year continued in the second quarter as SynAct Pharma made additional progress on its pipeline. The Covid-19 pandemic has certainly added complexity, but we have clear priorities, and our attractive project pipeline is progressing well. Our future is bright, and the second half of 2021 promises to be another busy period for us,” said SynAct Pharma’s CEO Jeppe Øvlesen.Summary of Half-Year 2021 interim report Second quarter (2021-04-01 – 2021-06-30) · Consolidated net sales

Lipum AB - interim report for the period January - June 2021

Press release: Umeå, 27 August, 2021. Lipum AB has published the interim report for period January to June 2021. Below is a brief summary, a complete report (only in Swedish) is available on the company's website .CEO Einar Pontén comments: “Lipum has reached a stage when we are preparing for clinical trials. Important intermediate goals have been achieved during the first half of the year. Toxicology- and safety studies are progressing according to plan as well as the upscaling of the production process of our drug candidate SOL-116”. Financial

BICO has acquired Advanced BioMatrix, an innovative company focused on 3D applications, to, together, ensure a market leading portfolio of bioinks and reagents

The USD 15 million deal marks BICO’s sixth acquisition this year, and further strengthening the company’s status as a leader in Bio Convergence.BICO, the leading Bio Convergence company, has acquired all outstanding shares in Advanced BioMatrix Corp. (Advanced BioMatrix), an American company focusing on 3D research applications. The Advanced BioMatrix portfolio includes collagen bioinks, high purity extracellular matrix proteins, chemically modified proteins and polysaccharides, and other reagents and cell assays, sold to research institutions, and pharmaceutical and biotech companies. The

Zalaris awarded ‘Best Payroll & HR Solutions Provider – Sweden’ at Scandinavian Business Awards

Zalaris ASA, a leading provider of Outsourced Payroll and HR services, is happy to announce it has been awarded the Best Payroll & HR Solutions Provider – Sweden at the Scandinavian Business Awards by EU Business News.EU Business News is a quarterly online magazine and B2B platform designed to inform readers of the latest market developments across Europe and is produced by the larger publishing house AI Global Media. Circulated to 54,000 C-suite executives and decision makers across Europe and alongside their online publication, they host a series of annual award programmes dedicated to

Principal shareholders issue call options to senior executives in SyntheticMR

SyntheticMR AB (publ) (”SyntheticMR”) announced today that leading executives (CEO and Head of US region) agreed on the purchase of a total of 300 000 call options. The options are issued by SyntheticMR’s principal shareholders (Nortal Investments AB, managed by Staffan Persson), founder (Marcel Warntjes) and Chairman of the Board (Johan Sedihn), which means there is no dilution for other shareholders. Holders have the right to acquire one (1) share in SyntheticMR for each call option. The duration of the incentive program is almost 5 years and exercising the call options can take place

The Chinese premium chain City Shop to launch DUG in its stores

City Shop is one of Shanghai’s largest chain stores with a clear focus on premium products and a high level of service. From September, City Shop will offer its customers Veg of Lund’s plant-based drink DUG[®] on the shelves.City Shop was established in 1995 with the goal of offering a wide range of food with high quality and best service. Today, City Shop has 13 stores in Shanghai's central residential areas and two stores in Beijing. “The fact that Veg of Lund has an agreement with City Shop gives us access to and an opportunity to expose our brand to purchasing power and conscious

LeadDesk’s organic growth and acquisitions fire up an excellent start to the year

LeadDesk Ltd Unofficial Translation of Press Release 27/8/2021 at 9.05 am. In case the document differs from the original, the Finnish version prevails.LeadDesk Ltd Half Year Financial Statement 1/1–30/6/2021 Figures in parenthesis refer to the equivalent period in the previous year, unless otherwise stated.  (Unaudited)   January–June 2021 ·Revenue EUR 12,022 (6,211) thousand, growth 93.6% · Comparable revenue EUR 12,542* (10,917**) thousand, growth 14.9% · Annual recurring revenue EUR 19 059 (9,704) thousand, growth 96,4% · EBITDA EUR 1,868 (623) thousand, 15.5 (

DBP International AB: The EC/CA submission for SI-053 has been sent to the Netherlands

Double Bond Pharmaceutical International AB (publ) ("DBP") takes another step towards the start of the phase 1 multinational multicentral clinical trial of its front-line product SI-053 in patients with glioblastoma - the Ethical Committee/Competent Authority submissions for SI-053 in The Netherlands has also been sent.As previously was reported the Clinical Trial Application (CTA) was sent and the CTA concerned 3 sites in Germany. With the current submission in the Netherlands DBP adds additionally a site for the trial. The process

AlzeCure’s ACD856 demonstrates good tolerability in Phase I clinical trial and is approved for additional doses

Stockholm, Sweden, August 27, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received approval from the Medical Products Agency to be able to give additional doses of ACD856 in the clinical phase I study (single ascending dose, SAD) with ACD856, as its good tolerability enables higher doses to be tested.Data from the SAD study establish that ACD856, the lead candidate drug

Cinclus Pharma Appoints Maria Engström as Chief Financial Officer

Stockholm, Sweden: Cinclus Pharma Holding AB (“Cinclus Pharma”), a biopharmaceutical company focused on the development of a novel treatment for gastroesophageal reflux disease (“GERD”), today announced the appointment of Maria Engström as Chief Financial Officer (CFO).  Maria has extensive experience in the pharmaceutical industry and most recently from Sedana Medical where she was CFO from 2017 to early 2021.Maria Engström assumed the position already in August 2021.   ” The company are delighted in having recruited Maria Engström to Cinclus Pharma” said Christer Ahlberg, CEO. "Maria

Eltel signs 5G agreement in Norway worth 12-16 million euros

Eltel Norway has signed a project agreement with Telenor to upgrade its telecommunications network with 5G technology. The agreement is worth about 12-16 million euros.Through the project, which runs during 2022, Eltel is strengthening its leading position in the Norwegian market regarding the expansion and modernisation of telecommunications networks through 5G. Further information:Elin Otter, Director, Communications and Investor RelationsPhone: +46 72 595 4692, elin.otter@eltelnetworks.com About EltelEltel is a leading Nordic field service provider for communication and power

HR Leaders from Spotify and Husqvarna Join Bambuser Advisory Board as Company’s Growth Surge Continues

Live Video Shopping pioneer reinforces commitment to excellence in company culture to maintain status among most desirable workplace in technology Stockholm – 27 August 2021 – Interactive live video shopping provider Bambuser today announced that prominent human resource experts Anne-Marie Andric, VP of People & Organization at Husqvarna Group, and Katarina Berg, CHRO of Spotify, are joining the company’s advisory board. The addition of the new members demonstrates the company’s ongoing commitment to fostering a healthy company culture, which will enable it to continue attracting

Quickbit terminates mentoring agreement with Eminova

In connection with the listing on Nordic SME, Quickbit entered into a mentoring agreement with Eminova Fondkomission AB. According to Nordic SME’s rules a company must have a mentor during the first two years as a listed company at Nordic SME. As the two-year period prescribed by the agreement has expired, Quickbit has decided to terminate the mentoring agreement with Eminova as of the 22 September 2021.   For further information, please contact:Hammad Abuiseifan, CEO, Quickbit eu AB (publ)Hammad@quickbit.com+ 46 73 095 87 12 ------------------------------------ Quickbit

Mycronic receives order for an SLX system

Mycronic AB (publ) has received an order for an SLX system from a new customer in Asia. The order value is in the range of USD 4-6 million. Delivery of the system is planned for the third quarter of 2022. The SLX laser mask writer meets rising demand for photomasks for the semiconductor industry and a future need for replacement and modernization. Photomasks manufactured by laser mask writers are of high importance and account for 70-75 percent of all photomasks produced for semiconductor manufacturing. SLX is a new and modern mask writer based on the same technology as Mycronic’s mask

Karnov Group releases industry report ‘Future Lawyer 2021’

Mental health is a taboo according to Scandinavian legal professionalsToday Karnov Group Denmark, Norstedts Juridik and Karnov Group Norway are launching the industry report Future Lawyer 2021. The report is the largest of its kind in Scandinavia and is based on data from 3379 full time legal professionals from Denmark, Sweden and Norway. The data is gathered and analysed by the independent Swedish agency, Augur. “It is my hope that the insights reported this year will help strengthen the legal industry, whether you are employed in the public or corporate sector or at a law firm. My hope

Zengun Group AB (publ) INTERIM REPORT FOR 1 APRIL TO 30 JUNE 2021

“Our customers displayed their continued confidence in us during the quarter. Our order book and orders received are at record-high levels and we are now coming out of a period with low production rates.” Mick Salonen Högberg, Managing Director and CEOSECOND QUARTER · Net turnover amounted to MSEK 420.1 (709.9). · EBITDA totalled MSEK 22.3 (28.7), corresponding to an EBITDA margin of 5.3% (4.0). · Earnings before tax amounted to MSEK 6.7 (13.3). · Operating cash flow was MSEK -18.3 (62.7) · Orders received totalled MSEK 972 (320). FIRST SIX MONTHS · Net turnover

ZINZINO AB (PUBL): INTERIM REPORT SECOND QUARTER 2021

INCREASED PROFIT FORECAST AFTER ANOTHER STRONG QUARTERThe second quarter of 2021 was yet another quarter in which good sales growth was combined with high profitability. Total revenues in the Group increased by 18% and amounted to SEK 322.4 (274.3) million. EBITDA result amounted to SEK 33.4 (16.0) million for the quarter and the EBITDA margin amounted to 10.4% (5.8%). The margin improvement is achieved through economies of scale due to improved efficiency in IT systems, logistics and within the organization. During the quarter, sales started in India, and Malaysia achieved full market

Scout Gaming publishes Q2 2021: Total revenues increased 121% to SEKm 13.9

”We had a busy quarter with the Euro 2020 as the main focus for the Group. Operator Trading Index grew with 203%. Total revenues increased with 121% to SEKm 13.9. The active user base cross our network partners have continued to grow substantially. Compared to average monthly users of the second quarter last year we experienced a growth of 302%. Strategically, we strive to optimize our marketing to support long-term growth. We use the start of major events such as Premier League, Euros or World Cup as aggressive growth-drivers. The market leading Norwegian operator Norsk Tipping has soft-

Tradedoubler Interim Report January - June 2021

The second quarter April – June 2021 · Total revenue amounted to SEK 333 M (287) an increase of 16% or 21% adjusted for changes in exchange rates compared to the same period last year.  · Gross profit was SEK 67 M (64), an increase of 4% or 9% adjusted for changes in exchange rates. Gross margin was 20.2% (22.4).  · Operating costs excluding depreciation and change related items were SEK 51M (50), an increase of 1% or 4% adjusted for changes in exchange rates.  · EBITDA amounted to SEK 16 M (14). Adjusted for change related items, EBITDA was SEK 17 M (14).  ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top